Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis
Schizophrenia Bulletin · 2026
DOI: 10.1093/schbul/sbag023 ↗Kurz gefasst
Leitlinie in der Zeitschrift Schizophrenia Bulletin, 2026. Verfasst von Caroline Hynes-Ryan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department And Research and Innovation Hub, St John of God University Hospital, Dublin A94 FH92, Ireland. Hauptthemen laut MEDLINE: Antipsychotic Agents, Psychotic Disorders, Practice Guidelines as Topic, Hyperprolactinemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Research Board, Australian Research Training Program scholarship RANZCP Foundation Partners PhD scholarship.
Abstract (Originalsprache)
Background
Early intervention in first-episode psychosis (FEP) is critical for long-term outcomes with antipsychotic medicines among the primary treatment options. However, existing clinical practice guidelines (CPGs) do not provide sex-specific recommendations, despite females experiencing distinct vulnerabilities to antipsychotic side-effects. In particular, hyperprolactinemia and cardiometabolic side-effects are associated with substantial subjective distress and potential long-term physical health risks for females across the reproductive lifespan. We aimed therefore to develop a CPG on the preferred antipsychotic medicines for females experiencing FEP. Study Design An international multidisciplinary panel, including experts-by-experience, used the GRADE-ADOLOPMENT process and AGREE II framework to adapt existing FEP guidelines for adults and adolescents. Key health questions were developed through stakeholder consultation and literature review. Critically important patient outcomes were prioritized, and evidence was synthesized on side-effect profiles, with recommendations agreed by consensus. The guideline algorithm was field-tested and externally reviewed by experts. Study Results Prolactin-elevation and cardiometabolic side-effects were prioritized in antipsychotic medicine selection for females. Medicines with higher risks—first-generation antipsychotics, olanzapine, quetiapine, risperidone, paliperidone, and amisulpride—are not recommended first-line. Aripiprazole is recommended as the preferred first-choice due to its consistently favorable prolactin and cardiometabolic profile. Alternative options with low or low-to-medium risk profiles are recommended for adults and adolescents, supported by shared decision-making tools.
Conclusions
This is the first CPG addressing antipsychotic choice for females with FEP. By prioritizing critically important patient outcomes and lived experience, the guideline supports safer, sex-sensitive prescribing for females that may improve treatment acceptability, adherence, and equity in psychosis care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department And Research and Innovation Hub, St John of God University Hospital, Dublin A94 FH92, Ireland.
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin D02 V951, Ireland.
- Department of Psychiatry, University of Oxford, Oxford OX3 7JX, United Kingdom.
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, SE5 8AB, United Kingdom.
- National Psychosis Unit, South London and Maudsley NHS Foundation Trust, London BR3 3BX, United Kingdom.
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, United Kingdom.
ORCID-Profile: Aoife Carolan, Sean Halstead, Brian O'Donoghue
Förderung
- Health Research Board
- Australian Research Training Program scholarship RANZCP Foundation Partners PhD scholarship
Zitieren
APA
Hynes-Ryan, C., Keating, D., Carolan, A., Brand, B., Dazzan, P., Gaughran, F., Hahn, M., Halstead, S., Harrington, S. M., Hartnett, Y., Kelleher, I., Lyne, J., McNicholas, F., O'Connor, K., Perry, B., Sadowska, E., O'Donoghue, B., & Sommer, I. E. (2026). Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbag023
Vancouver
Hynes-Ryan C, Keating D, Carolan A, Brand B, Dazzan P, Gaughran F, et al. Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis. Schizophrenia Bulletin. 2026. doi:10.1093/schbul/sbag023
BibTeX
@article{HynesRyan2026,
author = {Hynes-Ryan, Caroline and Keating, Dolores and Carolan, Aoife and Brand, Bodyl and Dazzan, Paola and Gaughran, Fiona and Hahn, Margaret and Halstead, Sean and Harrington, Sophie Mae and Hartnett, Yvonne and Kelleher, Ian and Lyne, John and McNicholas, Fiona and O'Connor, Karen and Perry, Benjamin and Sadowska, Ewa and O'Donoghue, Brian and Sommer, Iris E},
title = {Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis},
journal = {Schizophrenia Bulletin},
year = {2026},
doi = {10.1093/schbul/sbag023}
}
EUVIMED